$6 Million Trade Highlights Pfizer Inc. (PFE) Options Feeding Frenzy

Pfizer Inc. (NYSE:PFE) options traders are making major moves amid today's tax inversion hoopla

by Josh Selway

Published on Apr 5, 2016 at 3:36 PM

Pfizer Inc. (NYSE:PFE) is up 1.8% at $31.28, with today's volume nearly doubling its previous annual high, amid the potentially damaging news surrounding its merger with Allergan plc Ordinary Shares (NYSE:AGN). In fact, Reuters reported this afternoon that PFE is now leaning toward walking away from the deal, and options volume is surging as a result.

PFE's 30-day at-the-money implied volatility has jumped almost 16% to 19.5%, reflecting increased volatility expectations. Further, options volume is four times the expected intraday total, and on pace to surpass the Aug. 4 high, thanks to several large-block trades.

According to the International Securities Exchange (ISE), it looks like one trader simultaneously bought to open identical 21,000-contract blocks of the January 2017 28-strike put and 32-strike call for $1.38 and $1.52 per contract, respectively. The volatility strategy -- known as a "long strangle" -- was opened for a net debit of $2.90 per pair of contracts, or nearly $6.1 million (net debit * 100 shares per contract * number of spreads). The buyer will make money the lower PFE falls beneath $25.10 (put strike minus net debit) or rallies north of $34.90 (call strike plus net debit) by January options expiration.

Elsewhere, a sale of 10,000 Sept. 30 calls crossed earlier, as well as a sale of nearly 11,500 January 2017 30-strike calls. It's possible these were traders cashing out of their positions amid today's rally in the shares, according to Trade-Alert

Before today, it had been PFE puts that were in high demand. The stock's 10-day put/call volume ratio at the ISE, Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) comes in at 1.10 -- in the 87th percentile of its annual range. However, options were popular on both sides of the aisle, as put and call open interest are at annual highs.

Pfizer Inc.'s (NYSE:PFE) rally has it on pace for its best finish in months, with help from news that the company's psoriatic arthritis drug, tofacitinib, met its main goals in a phase 3 study. However, the stock could run into a wall in the $31.50-$32 area, which acted as support in the latter half of 2015.  

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.


A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Look Who's Going Bankrupt Next in America
Porter Stansberry is making a concerning prediction.
Apparel Name Boosted By Earnings Beat
Three analysts have moved their price targets down to $60
Black & Decker Withdraws 2020 Guidance, Cuts Non-Essential Staff
Black & Decker said it would reduce any non-essential staff and decided to withdraw its 2020 forecast
Look Who's Going Bankrupt Next in America
Porter Stansberry is making a concerning prediction.